The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries
Open accessAbstract
BACKGROUND: Investing in late-stage clinical trials, trial sites, and production capacity for new health products could improve access to vaccines, therapeutics, and infectious disease diagnostics in middle-income countries. This study assesses the case for such investment in three of these countries: India, Kenya, and South Africa. METHODS: We applied investment case modelling and assessed how many cases, deaths, and disability-adjusted life years (DALYs) could be averted from the development and manufacturing of new technologies (therapeutics and vaccines) in these countries from 2021 to 2036, for five diseases-HIV, tuberculosis, malaria, pneumonia, and diarrhoeal diseases. We also estimated the economic benefits that might accrue from making these investments and we developed benefit-cost ratios for each of the three middle-income countries. Our modelling applies two investment case perspectives: a societal perspective with all costs and benefits measured at the societal level, and a country perspective to estimate how much health and economic benefit accrues to each middle-income country for every dollar invested in clinical trials and manufacturing by the middle-income country government. For each perspective, we modelled two scenarios: one that considers only domestic health and economic benefits; and one that includes regional health and economic benefits. In the regional scenarios, we assumed that new products developed and manufactured in India would benefit eight countries in south Asia, whereas new products developed and manufactured in Kenya would benefit all 21 countries in the Common Market for Eastern and Southern Africa (COMESA). We also assumed that all 16 countries in the Southern African Development Community (SADC) would benefit from products developed and manufactured in South Africa. FINDINGS: From 2021 to 2036, product development and manufacturing in Kenya could avert 4·44 million deaths and 206·27 million DALYs in the COMESA region. In South Africa, it could prevent 5·19 million deaths and 253·83 million DALYs in the SADC region. In India, it could avert 9·76 million deaths and 374·42 million DALYs in south Asia. Economic returns would be especially high if new tools were produced for regional markets rather than for domestic markets only. Under a societal perspective, regional returns outweigh investments by a factor of 20·51 in Kenya, 33·27 in South Africa, and 66·56 in India. Under a country perspective, the regional benefit-cost ratios amount to 60·71 in India, 8·78 in Kenya, and 11·88 in South Africa. INTERPRETATION: Our study supports the creation of regional hubs for clinical trials and product manufacturing compared with narrow national efforts. FUNDING: Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global health 2035: a world converging within a generation
Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A., Bustreo, F., Evans, D., Feachem, R. G. A., Frenk, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62105-4 · Cited by 1,220
Self-citation[Global health 2035: a world converging within a generation].
Jamison, D. T. T., Summers, L. H., Alleyne, G. A. O., Arrow, K. J., Berkley, S., Binagwaho, A., Bustreo, F., EVANS, D. B., Feachem, R. G., Frenk, J. M., et al. (2015) · PubMed · Cited by 943
Self-citationFinal Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605
Adjusting for Inflation and Currency Changes Within Health Economic Studies
Turner, H. C., Lauer, J. A., Tran, B. X., Teerawattananon, Y., & Jit, M. (2019) · Value in Health · doi:10.1016/j.jval.2019.03.021 · Cited by 339
Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis
Burnett, E., Parashar, U. D., & Tate, J. E. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30262-x · Cited by 206
Verguet, S., Olson, Z. D., Babigumira, J. B., Desalegn, D., Johansson, K. A., Kruk, M. E., Levin, C., Nugent, R. A., Pecenka, C. J., Shrime, M. G., et al. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70346-8 · Cited by 120
Vaccines and global health: In search of a sustainable model for vaccine development and delivery
Rappuoli, R., BLACK, S. B., & Bloom, D. E. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2888 · Cited by 113
Young, R., Bekele, T., Gunn, A. H., Chapman, N., Chowdhary, V., Corrigan, K. L., Dahora, L. C., Martínez, S., Permar, S. R., Persson, J., et al. (2018) · Gates Open Research · doi:10.12688/gatesopenres.12817.2 · Cited by 38
Self-citationHow COVID spurred Africa to plot a vaccines revolution
Irwin, A. (2021) · Nature · doi:10.1038/d41586-021-01048-1 · Cited by 36
Young, R., Bekele, T., Gunn, A. H., Chapman, N., Chowdhary, V., Corrigan, K. L., Dahora, L. C., Martínez, S., Permar, S. R., Persson, J., et al. (2018) · Gates Open Research · doi:10.12688/gatesopenres.12817.1 · Cited by 26
Self-citation
Cited by
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125
Self-citationHurvitz, N., & Ilan, Y. (2023) · Clinics and Practice · doi:10.3390/clinpract13040089 · Cited by 36
Behind-the-Scenes Investment for Equity in Global Health Research
Haberer, J. E., & Boum, Y. (2023) · New England Journal of Medicine · doi:10.1056/nejmp2213809 · Cited by 23
European priority review vouchers for neglected disease product development
Ridley, D. B., Lasanta, A. M., Jones, F. S., & Ridley, S. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-013686 · Cited by 8
Tomeny, E., Hampton, T., Tran, P. B., Roșu, L., Phiri, M. D., Haigh, K. A., Nidoi, J., Wingfield, T., & Worrall, E. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01410-x · Cited by 6
Metadata
- Authors
- Schäferhoff, M., Zimmerman, A., Diab, M. M., Mao, W., Chowdhary, V., Gill, D., Karanja, R., Madikizela, M., Ogbuoji, O., & Yamey, G.
- Affiliations
- Duke University (US)
- Policy Cures (AU)
- University of Pretoria (ZA)
- Corresponding author
- Schäferhoff, Marco
- ORCID
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 10
- Issue
- 7
- Pages
- e1045-e1052
- ISSN
- 2214-109X (ISSN-L)
- PMC
- PMC9210258
- OpenAlex
- W4282942737
- Cited by
- 11
- References
- 15
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 1
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Global Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Biotechnology and Related Fields
- Keywords
- late-stage clinical trials, pharmaceutical manufacturing capacity, benefit-cost ratio, infectious disease therapeutics, vaccines, HIV, tuberculosis, malaria, pneumonia, diarrhoeal diseases, middle-income countries, disability-adjusted life years, India, Kenya, South Africa, South Asia, COMESA, SADC
- MeSH terms
- Clinical Trials as Topic, Communicable Diseases, Cost-Benefit Analysis, Developing Countries, Humans, India, Investments
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries. https://app.cochat.ai/papers/10.1016/s2214-109x(22)00206-6
- The paper
- Schäferhoff, M., Zimmerman, A., Diab, M. M., Mao, W., Chowdhary, V., Gill, D., Karanja, R., Madikizela, M., Ogbuoji, O., & Yamey, G. (2022). Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(22)00206-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.